Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin
Journal of Magnetic Resonance Imaging, 05/03/2012Chang YC et al.
Dynamic contrast–enhanced (DCE) magnetic resonance imaging (MRI) enables a functional analysis of the treatment response of nonsmall–cell lung cancer (NSCLC). MRI parametric histogram has the potential to predict early treatment response of combined bevacizumab, gemcitabine, and cisplatin.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.